









Markets
/
Stocks
/
nasdaq-rcus
/

Arcus Biosciences Inc

RCUS

12.450USD

+0.420+3.49%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.32BMarket Cap

LossP/E TTM



Arcus Biosciences Inc

12.450

+0.420+3.49%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

15 / 507

Overall Ranking

96 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

29.182

Target Price

+148.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 130.36% year-on-year.

Fairly Valued

The company’s latest PE is -3.83, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 104.25M shares, increasing 4.75% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 6.54M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.46, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 160.00M, representing a year-over-year increase of 310.26%, while its net profit experienced a year-over-year increase of 100.00%.

Score

Industry at a Glance

Previous score

8.46

Change



Financials

6.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.79

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -3.83, which is -4.38% below the recent high of -3.66 and -29.99% above the recent low of -4.98.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 15/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.15, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Arcus Biosciences Inc is 25.00, with a high of 52.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.15

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

29.182

Target Price

+142.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Arcus Biosciences Inc

RCUS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 8.59, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 12.99 and the support level at 10.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.54

Change

0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.093

Buy

RSI(14)

70.000

Buy

STOCH(KDJ)(9,3,3)

81.073

Buy

ATR(14)

0.588

High Vlolatility

CCI(14)

173.090

Buy

Williams %R

2.387

Overbought

TRIX(12,20)

0.774

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

11.864

Buy

MA10

11.749

Buy

MA20

11.240

Buy

MA50

10.241

Buy

MA100

9.535

Buy

MA200

10.728

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 98.12%, representing a quarter-over-quarter decrease of 2.28%. The largest institutional shareholder is The Vanguard, holding a total of 6.54M shares, representing 6.15% of shares outstanding, with 4.64% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Gilead Sciences Inc

31.42M

BlackRock Institutional Trust Company, N.A.

9.68M

+13.37%

The Vanguard Group, Inc.

Star Investors

6.68M

+24.15%

Point72 Asset Management, L.P.

Star Investors

2.87M

+43.62%

Woodline Partners LP

5.13M

+45.50%

Suvretta Capital Management, LLC

2.56M

+344.48%

State Street Global Advisors (US)

3.70M

+23.47%

Rosen Terry Jay

2.57M

-15.53%

Fidelity Management & Research Company LLC

4.12M

+10.88%

Dimensional Fund Advisors, L.P.

1.72M

+1.16%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.14, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.73. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.